One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Burford Capital Limited logo
Burford Capital Limited BUR
$ 3.05 -0.65%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Burford Capital Limited Balance Sheet 2025-2011 | BUR

Brief overview of Burford Capital Limited's assets and capital

The balance sheet is assessed across five available annual reports spanning 2020 to 2025.

Total assets increased by +113.2%, from $3.1 billion to $6.6 billion. A CAGR near 16.3% points to substantial expansion.

Liabilities grew faster than assets: +141.8% versus +113.2%. A substantial part of expansion was externally funded.

The equity ratio is 36.9% versus 54.6% five periods ago. Capitalization remains workable.

Each unit of equity supports about 0.64x of net debt. The level is not critical, though flexibility is narrower.

Cash accounts for 8.5% of assets versus 10.3% initially. The change indicates the degree of financial flexibility.

Accumulated earnings ended at $1.8 billion, a change of . They remain an important part of the capital base.

Conclusion

The balance sheet gives no single signal for Burford Capital Limited: some indicators are sound, while leverage or capitalization needs attention.

Annual Balance Sheet Burford Capital Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

1.56 B 1.29 B 1.31 B 1.16 B - - - - -135 M -115 M -45.4 M -93.6 M -57.7 M -25.6 M -8.9 M

Long Term Debt

2.13 B 1.76 B 1.53 B 1.27 B - - - - - - - - - - -

Total Liabilities

3.51 B 2.92 B 2.63 B 1.9 B - 1.45 B 1.54 B 956 M 701 M 372 M 160 M 151 M 24.6 M 12.9 M 12.6 M

Retained Earnings

1.8 B 1.77 B 1.65 B 1.07 B - - - - - - - - - - -

Total Assets

6.64 B 6.18 B 5.84 B 4.29 B - 3.11 B 3.04 B 2.32 B 1.5 B 968 M 594 M 533 M 376 M 345 M 322 M

Cash and Cash Equivalents

566 M 470 M 221 M 108 M - 322 M 187 M 266 M 135 M - - - - - -

Book Value

3.13 B 3.26 B 3.21 B 2.39 B - 1.66 B 1.5 B 1.36 B 799 M 596 M 434 M 383 M 352 M 332 M 309 M

Total Shareholders Equity

2.45 B 2.42 B 2.29 B 1.74 B - 1.7 B 1.53 B - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Burford Capital Limited

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.4 B 2.4 B 2.14 B 1.78 B 1.76 B 1.57 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

2.8 B 2.76 B 3.5 B 3.1 B 3.02 B 2.63 B - - - - - - - - 1.45 B - - - 1.54 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

157 M 169 M 1.85 B 1.87 B 1.8 B 1.65 B - - - - - - - - 1.05 B - - - 923 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

4.27 B 4.27 B 6.69 B 6.33 B 6.18 B 5.84 B - - - - - - - - 3.11 B - - - 3.04 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

697 M 703 M 678 M 372 M 487 M 221 M - - - - - - - - 322 M - - - 187 M - - - 266 M - - - 135 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

1.47 B 1.51 B 3.19 B 3.23 B 3.16 B 3.21 B - - - - - - - - 1.66 B - - - 1.5 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

819 M 828 M 2.5 B 2.5 B 2.43 B 2.29 B - - - - - - - - 1.66 B - - - 1.5 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Burford Capital Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.15 -7.26 % $ 61.7 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Satsuma Pharmaceuticals Satsuma Pharmaceuticals
STSA
- -0.9 % $ 36.5 M usaUSA
SpringWorks Therapeutics SpringWorks Therapeutics
SWTX
- - $ 3.48 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 238.9 1.95 % $ 14.5 B danmarkDanmark
Trevena Trevena
TRVN
- -46.58 % $ 31.8 M usaUSA
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Y-mAbs Therapeutics Y-mAbs Therapeutics
YMAB
- - $ 382 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 3.55 8.9 % $ 212 M franceFrance
Turning Point Therapeutics Turning Point Therapeutics
TPTX
- -0.13 % $ 3.73 B usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.2 1.0 % $ 1.22 B usaUSA
Annovis Bio Annovis Bio
ANVS
$ 0.99 0.01 % $ 20.3 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Kodiak Sciences Kodiak Sciences
KOD
$ 87.72 -5.65 % $ 4.67 B usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
NeuBase Therapeutics NeuBase Therapeutics
NBSE
- -1.56 % $ 12.3 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Scopus BioPharma Scopus BioPharma
SCPS
- -48.37 % $ 3.71 M usaUSA
scPharmaceuticals scPharmaceuticals
SCPH
- - $ 218 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 20.2 1.81 % $ 6.33 B usaUSA
Inozyme Pharma Inozyme Pharma
INZY
- - $ 207 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 11.18 -1.93 % $ 416 M usaUSA
Sierra Oncology Sierra Oncology
SRRA
- -0.05 % $ 1.34 B canadaCanada
Vaccinex Vaccinex
VCNX
- -61.37 % $ 654 K usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA